ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,519,610 | -14.3% | 461,299 | -2.9% | 0.02% | -6.2% |
| Q2 2023 | $14,611,244 | +96843.0% | 475,317 | +13.6% | 0.02% | -15.8% |
| Q1 2023 | $15,072 | -7.2% | 418,306 | +1.7% | 0.02% | -13.6% |
| Q4 2022 | $16,248 | -99.9% | 411,142 | +6.4% | 0.02% | -4.3% |
| Q3 2022 | $15,520,000 | +7.1% | 386,253 | +12.0% | 0.02% | +9.5% |
| Q2 2022 | $14,494,000 | +34.0% | 344,778 | +24.2% | 0.02% | +50.0% |
| Q1 2022 | $10,816,000 | -4.0% | 277,607 | -1.8% | 0.01% | 0.0% |
| Q4 2021 | $11,264,000 | +14.4% | 282,663 | +3.7% | 0.01% | +7.7% |
| Q3 2021 | $9,848,000 | -16.9% | 272,502 | -5.8% | 0.01% | -18.8% |
| Q2 2021 | $11,857,000 | -8.4% | 289,256 | -2.5% | 0.02% | -11.1% |
| Q1 2021 | $12,947,000 | +165.7% | 296,803 | +204.8% | 0.02% | +157.1% |
| Q4 2020 | $4,873,000 | +50.9% | 97,361 | +26.8% | 0.01% | +40.0% |
| Q3 2020 | $3,230,000 | – | 76,769 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |